BamSEC and AlphaSense Join Forces
Learn More

Aquestive Therapeutics Inc.

NASDAQ: AQST    
Share price (1/3/25): $3.58    
Market cap (1/3/25): $326 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.40
from 10-K 10 pages Material contract
12/34/56
EX-10.3
from 8-K 22 pages Royalty Right Agreement Dated as of November 1, 2023 Between Aquestive Therapeutics, Inc. and the Purchaser Named Herein
12/34/56
EX-10.2
from 8-K 63 pages Collateral Agreement Dated as of November 1, 2023 Among Aquestive Therapeutics, Inc., as Issuer, the Other Grantors From Time to Time Party Hereto, U.S. Bank Trust Company, National Association, as Trustee, and U.S. Bank Trust Company, National Association, as Collateral Agent
12/34/56
EX-10.1
from 8-K 42 pages Purchase Agreement Dated November 1, 2023 Between Aquestive Therapeutics, Inc. and the Purchaser Named Herein $45,000,000 13.5% Senior Secured Notes Due 2028
12/34/56
EX-10.1
from 8-K 11 pages Material contract
12/34/56
EX-10.29
from 10-K 50 pages The Symbol “[****]” Denotes Places Where Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. License Agreement by and Between Aquestive Therapeutics, Inc. and Otter Pharmaceuticals, LLC Dated as of October 26, 2022
12/34/56
EX-10.22
from 10-K 10 pages Material contract
12/34/56
EX-10.9
from 10-K 4 pages The Symbol “[****]” Denotes Places Where Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Amendment No. 11 to Commercial Exploitation Agreement
12/34/56
EX-10.1
from 10-Q 66 pages The Symbol “[****]” Denotes Places Where Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material, and (II) Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. License and Supply Agreement by and Between Aquestive Therapeutics, Inc. and Atnahs Pharma Uk Limited Dated as of September 26, 2022
12/34/56
EX-10.1
from 10-Q 19 pages Material contract
12/34/56
EX-10.1
from 8-K 32 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 6 pages Amendment No. 2 to Purchase Agreement
12/34/56
EX-10.1
from 8-K 16 pages Separation Agreement
12/34/56
EX-10.1
from 10-Q 55 pages Business.29027546.1 Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. License, Development and Supply Agreement by and Between Aquestive Therapeutics, Inc. and Haisco Pharmaceutical Group Co, Ltd. Dated as of March 3rd, 2022
12/34/56
EX-10.2
from 8-K 14 pages Material contract
12/34/56
EX-10.1
from 8-K 37 pages Material contract
12/34/56
EX-10.26
from 10-K 3 pages Material contract
12/34/56
EX-10.25
from 10-K 3 pages Material contract
12/34/56
EX-10.1
from 8-K 12 pages Material contract
12/34/56
EX-10.1
from 8-K 9 pages Material contract
12/34/56